XOMA Royalty (XOMA) to Release Quarterly Earnings on Wednesday

XOMA Royalty (NASDAQ:XOMA) is projected to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect XOMA Royalty to announce earnings of $0.18 per share and revenue of $13.91 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The company had revenue of $12.32 million during the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. On average, analysts expect XOMA Royalty to post $1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $40.17 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59. The firm has a market cap of $503.77 million, a PE ratio of 25.59 and a beta of 0.86. The company has a 50-day moving average of $41.61 and a two-hundred day moving average of $35.30. XOMA Royalty has a 1-year low of $22.29 and a 1-year high of $45.22.

Hedge Funds Weigh In On XOMA Royalty

Several institutional investors have recently modified their holdings of the business. Opaleye Management Inc. increased its position in shares of XOMA Royalty by 14.7% during the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after acquiring an additional 37,503 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of XOMA Royalty in the fourth quarter valued at $237,000. Panagora Asset Management Inc. boosted its holdings in XOMA Royalty by 24.2% in the fourth quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock valued at $564,000 after purchasing an additional 4,135 shares during the period. Barclays PLC boosted its holdings in XOMA Royalty by 12.1% in the fourth quarter. Barclays PLC now owns 14,822 shares of the biotechnology company’s stock valued at $394,000 after purchasing an additional 1,598 shares during the period. Finally, State Street Corp grew its stake in XOMA Royalty by 4.7% during the 4th quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock worth $4,651,000 after purchasing an additional 7,873 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Weiss Ratings raised shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. HC Wainwright downgraded shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a report on Thursday, April 30th. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Benchmark lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, XOMA Royalty presently has a consensus rating of “Hold” and an average target price of $53.75.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.